The disadvantages of the new classification are that: (1) probands may move between categories within the spectrum over time; (2) the classification has currently no immediate implications on cancer surveillance protocols because further risk analyses are required; and (3) carriers of TP53 variants who do not fall into the P/LP variant category are not included in the new definition. Here, TP53 is linked to cancer.